Apolipoprotein e genotype is related to progression of white matter lesion load

Stroke

Volumn 40, Issue 10, 2009, Pages 3186-3190

  Godin, Ophélia ^a,b   Tzourio, Christophe ^a,b   Maillard, Pauline ^c,d   Alpérovitch, Annick ^a,b   Mazoyer, Bernard ^c,e,f   Dufouil, Carole ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CNRS CEA UMR 6232   (France)

^d UNIVERSITÉ DE CAEN   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

ApoE; Cerebrovascular; Elderly; Epidemiology; MRI

Indexed keywords

APOLIPOPROTEIN E;

AGED; ALLELE; ARTICLE; BRAIN DAMAGE; BRAIN SIZE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; WHITE MATTER LESION;

AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; COHORT STUDIES; DEMENTIA; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; NERVE FIBERS, MYELINATED; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX;

EID: 70349659477     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.555839     Document Type: Article

References (21)

1. Mayeux R, Stern Y, Ottman R, Tatemichi T, Tang MX, Maestre G, Ngai C, Tycko B, Ginsberg H. The apolipoprotein e4 allele in patients with Alzheimer's disease. Ann Neurol. 1993;34:752-754.
2. Horsburgh K, McCarron MO, White F, Nicoll JA. The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging. 2000;21:245-255.
3. Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, Smith AD. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience. 1995;69:757-761.
4. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol. 1996;148:2083-2095.
5. Cherbuin N, Leach LS, Christensen H, Anstey KJ. Neuroimaging and APOE genotype: a systematic qualitative review. Dement Geriatr Cogn Disord. 2007;24:348-362.
6. deGroot JC, deLeeuw FE, Oudkerk M, vanGijn J, Hofman A, Jolles J, Breteler MMB. Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol. 2002;52:335-341.
7. Kuller LH, Shemanski L, Manolio TA, Haan M, Fried L, Bryan N, Burke GL, Tracy R, Bhadelia R. Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke. 1998;29: 388-398.
8. Hirono N, Yasuda M, Tanimukai S, Kitagaki H, Mori E. Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. Stroke. 2000;31:1263-1268.
9. Van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM, Koudstaal PJ, Breteler MM. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol. 2004;55:570-575.
10. Schmidt R, Schmidt H, Fazekas F, Schumacher M, Niederkorn K, Kapeller P, Weinrauch V, Kostner GM. Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Stroke. 1997;28:951-956.
11. The 3C Study Group. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology. 2003;22:316-325.
12. Dufouil C, Richard F, Fievet N, Dartigues JF, Ritchie K, Tzourio C, Amouyel P, Alperovitch A. APOE genotype, cholesterol level, lipidlowering treatment, and dementia: the Three-City Study. Neurology. 2005;64:1531-1538.
13. Maillard P, Delcroix N, Crivello F, Dufouil C, Gicquel S, Joliot M, Tzourio-Mazoyer N, Alpérovitch A, Tzourio C, Mazoyer B. An automated procedure for the assessment of white matter hyperintensities on T2-MRI and its between-centre reproducibility evaluation on two large community databases. Neuroradiology. 2008;50:31-42.
14. de Leeuw FE, Richard F, de Groot JC, van Duijn CM, Hofman A, van Gijn J, Breteler MM. Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke. 2004;35:1057-1060.
15. Bronge L, Fernaeus SE, Blomberg M, Ingelson M, Lannfelt L, Isberg B, Wahlund LO. White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype. Dement Geriatr Cogn Disord. 1999;10: 89-96.
16. Kapeller P, Barber R, Vermeulen RJ, Ader H, Scheltens P, Freidl W, Almkvist O, Moretti M, delSer T, Vaghfeldt P, Enzinger C, Barkhof F, Inzitari D, Erkinjunti T, Schmidt R, Fazekas F. Visual rating of agerelated white matter changes on magnetic resonance imaging-scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke. 2003;34:441-445.
17. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752-758.
18. Tzourio C, Levy C, Dufouil C, Touboul PJ, Ducimetiere P, Alperovitch A. Low cerebral blood flow velocity and risk of white matter hyperintensities. Ann Neurol. 2001;49:411-414.
19. Szolnoki Z. Pathomechanism of leukoaraiosis: a molecular bridge between the genetic, biochemical, and clinical processes (a mitochondrial hypothesis). Neuromolecular Med. 2007;9:21-33.
20. Greenberg SM, Hyman BT. Cerebral amyloid angiopathy and apolipoprotein E: bad news for the good allele? Ann Neurol. 1997;41:701-702.
21. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66:23-29.